Basket | Login | Register

 
 
 
 

Spain

2012: National Dementia Strategies (diagnosis, treatment and research)

Background information about the National Dementia Strategy

Status and historical development of the National Dementia Strategy

Spain does not have a national dementia strategy. Led by the Spanish Alzheimer Federation (CEAFA), the “Alzheimer’s Alliance” (which includes a cross-section of national organisations such as Spanish Societies of Neurology, Geriatry, Primary Attention and the Foundation Pasqual Maragall) aims to ensure that a National Alzheimer Strategy is implemented. The Alliance was due to have a formal meeting with the Health Ministry to discuss a national plan, but the meeting was delayed due to forthcoming national elections in November 2011.

Treatment and research

Issues relating to medical treatment

The availability of medicines in general

Patients must pay 40% of the price of pharmaceutical products but for certain products there is a reduction of 90% with a maximum limit of EUR 2.64. However, certain groups of people do not have to make any payment. This includes pensioners, people receiving inpatient hospital care and people over the age of 65 with limited resources[1].

The availability of Alzheimer treatments

All four AD drugs are available in Spain.

Conditions surrounding the prescription and reimbursement of AD drugs

AD drugs are part of the reimbursement system. Treatment initiation and continuation is limited to specialists and the reimbursement system requires specialists to carry out an MMSE of patients. Reimbursement with acetylcholinesterase inhibitors is limited to people with Alzheimer’s disease with an MMSE score of 23 and below and with memantine for an MMSE score of 17 and below. There are no restrictions for people living alone or in nursing homes.

Prescription and reimbursement

Donepezil

Rivastigmine

Galantamine

Memantine

Available

Yes

Yes

Yes

Yes

Reimbursed

Yes

Yes

Yes

Yes

Initial drug reimbursed if prescribed by

Specialist doctor

Specialist doctor

Specialist doctor

Specialist doctor

Continuing treatment reimbursed if prescribed by

Specialist doctor

Specialist doctor

Specialist doctor

Specialist doctor

Required examinations

MMSE

MMSE

MMSE

MMSE

MMSE limits

23 and below

23 and below

23 and below

17 and below

Issues relating to research

Spain is involved in the EU Joint Programme – Neurodegenerative Disease Research (JPND) and is an Associate member of the Joint Action “Alzheimer Cooperative Valuation in Europe (ALCOVE)”.

[1] European Commission (2012): MISSOC – Mutual information system on social protection : Social protection in the Member States of the European Union, of the European Economic Area and in Switzerland : Comparative tables

 

 
 

Last Updated: Tuesday 14 May 2013

 

 
  • Acknowledgements

    The above information was published in the 2012 Dementia in Europe Yearbook as part of Alzheimer Europe's 2012 Work Plan which received funding from the European Union in the framework of the Health Programme. Alzheimer Europe gratefully acknowledges the support it has received from the Alzheimer Europe Foundation for the preparation and publication of its 2012 Yearbook.
  • European Union
 
 

Options